Avecho Biotechnology Limited released results for its Australian Phase I PK study characterizing the absorption profile of cannabidiol (CBD) from Avecho's proprietary CBD soft-gel product. The primary objective of the study was to determine the single dose pharmacokinetics (PK) of cannabidiol absorbed from a single 75 mg and 150 mg oral dose from proprietary CBD soft-gel products. This information is required for future product registration with the TGA or FDA. The 75 mg and 150 mg doses align with the TGA's down-scheduling of CBD, which has specified that future over-the-counter CBD products must have a maximum daily dose of 150 mg. The Study was conducted at CMAX in Adelaide with 16 healthy volunteers. Subjects received both doses over a period of two weeks, with each dose preceded by an overnight fast. Blood samples were collected for 48 hours after each dose and assayed for CBD content. All 16 subjects completed both treatment periods. The CBD absorption profile and pharmacokinetic parameters of both the 75 mg and 150 mg doses were well characterised. There was a linear relationship between doses with the average amount of drug absorbed from the 150 mg dose being approximately double that of the 75 mg dose. The two doses exhibit minor differences in delivery profile, with mean peak plasma concentrations for the 75 mg dose appearing 2 hours after dosing, whereas peak plasma concentrations for the 150 mg dose were evident three hours after dosing. The absorption period of the 150 mg dose was also longer, with CBD detected in the blood one week after dosing. Both doses of the CBD soft-gel were well tolerated, with all adverse events characterised as mild and no adverse events of concern related to the study medication.